{"id":7079,"date":"2026-08-13T10:52:35","date_gmt":"2026-08-13T10:52:35","guid":{"rendered":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/?p=7079"},"modified":"2026-08-13T10:52:38","modified_gmt":"2026-08-13T10:52:38","slug":"history-of-melanoma-immunotherapy","status":"publish","type":"post","link":"https:\/\/www.london-dermatology-centre.co.uk\/blog\/history-of-melanoma-immunotherapy\/","title":{"rendered":"The First Successful Melanoma Immunotherapy: A Breakthrough in Skin Cancer Care"},"content":{"rendered":"\n

Advanced melanoma was historically extremely difficult to treat once it could no longer be removed surgically or had spread to distant parts of the body. Early immunotherapies showed that altering your immune response could occasionally produce remarkable and durable tumour regression, while later checkpoint inhibitors made long-term disease control possible for a much larger proportion of patients.<\/p>\n\n\n\n

This transformation did not come from one single treatment. Early work with interleukin-2 and interferon helped establish immune-based cancer treatment, while discoveries involving CTLA-4 and PD-1 eventually led to modern checkpoint inhibitors such as ipilimumab, nivolumab and pembrolizumab. Understanding these milestones helps explain why melanoma became central to the development of modern cancer immunotherapy.<\/p>\n\n\n\n

What Was the First Successful Melanoma Immunotherapy?<\/strong><\/h2>\n\n\n\n

There is no single answer unless you define what successful means. In 1985, Steven Rosenberg and colleagues reported objective tumour regression after treatment with lymphokine-activated killer cells and recombinant IL-2, including a complete regression in a patient with metastatic melanoma. Later studies showed that high-dose IL-2 alone could produce durable complete responses in a small proportion of people with metastatic melanoma.<\/p>\n\n\n\n

High-dose IL-2 was approved in the United States for adults with metastatic melanoma in January 1998. Ipilimumab represented a different milestone in 2010\u20132011 because it became the first immune-checkpoint treatment shown in a randomised phase III trial to extend overall survival in advanced melanoma.<\/p>\n\n\n\n

Why Melanoma Became a Target for Immunotherapy<\/strong><\/h2>\n\n\n\n

Researchers discovered that your immune system could sometimes recognise melanoma cells, creating the possibility of strengthening this natural response through treatment. This suggested that the immune system might be able to play a role in controlling melanoma more effectively.<\/p>\n\n\n\n

The challenge was finding a way to make this immune response strong enough and persistent enough to control advanced disease. This became an important focus of research as scientists looked for ways to improve the body’s ability to recognise and attack melanoma cells.<\/p>\n\n\n\n

Early Treatments Focused on Cytokines<\/strong><\/h2>\n\n\n\n

Before checkpoint inhibitors, cytokines were among the most important immune-based treatments investigated for melanoma. Interferon-alpha and interleukin-2 both influenced immune activity, but they eventually occupied different roles in melanoma care.<\/p>\n\n\n\n

High-dose IL-2 became particularly important in metastatic melanoma because a small number of patients achieved remarkably durable complete tumour regression. Interferon alfa-2b became better known as an adjuvant treatment after surgery for selected people with high-risk melanoma. These treatments demonstrated the potential of immunotherapy but were limited by toxicity and by the relatively small proportion of patients who benefited.<\/p>\n\n\n\n

Interleukin-2 Produced Rare but Remarkably Durable Responses<\/strong><\/h2>\n\n\n\n

High-dose interleukin-2 provided early evidence that immunotherapy could sometimes achieve long-term control of metastatic melanoma. Across eight trials involving 270 patients, the objective response rate was 16%, including complete responses in 6% and partial responses in 10%, with some complete responses lasting for many years.<\/p>\n\n\n\n

Key Findings With High-Dose Interleukin-2<\/strong><\/p>\n\n\n\n

Aspect<\/strong><\/td>Finding<\/strong><\/td>What It Showed<\/strong><\/td>Why It Mattered<\/strong><\/td><\/tr><\/thead>
Patients studied<\/td>270 patients across eight trials<\/td>Provided evidence from multiple clinical studies<\/td>Strengthened understanding of IL-2 activity<\/td><\/tr>
Overall response<\/td>16% achieved an objective response<\/td>Some patients experienced measurable tumour reduction<\/td>Demonstrated potential for immunotherapy<\/td><\/tr>
Complete responses<\/td>6% achieved complete responses<\/td>Some patients had no detectable disease after treatment<\/td>Showed the possibility of deep responses<\/td><\/tr>
Partial responses<\/td>10% achieved partial responses<\/td>Tumour burden was reduced in some patients<\/td>Added further evidence of treatment activity<\/td><\/tr>
Long-term responses<\/td>Some complete responses persisted for many years<\/td>Responses could remain durable<\/td>Suggested immune treatment could provide prolonged disease control<\/td><\/tr>
Responses lasting over 30 months<\/td>No further disease progression was found during subsequent follow-up<\/td>Very durable control was possible in selected patients<\/td>Provided important evidence for lasting immunotherapy benefit<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n

Why IL-2 Was an Important Breakthrough<\/strong><\/h2>\n\n\n\n

IL-2 helped establish proof that manipulating your immune system could sometimes produce durable complete regression even when melanoma had spread. This led to US approval of high-dose aldesleukin for adults with metastatic melanoma in January 1998.<\/p>\n\n\n\n

However, most patients did not respond, and high-dose treatment could cause severe toxicity and required highly experienced specialist care. The large historical series reported treatment-related deaths as well as substantial acute toxicity, which greatly limited its suitability and encouraged the search for treatments with a better balance between benefit and risk.<\/p>\n\n\n\n

Long-Term Survival Was Transformed<\/strong><\/h2>\n\n\n\n
\"\"<\/figure>\n\n\n\n

The final 10-year CheckMate 067 results demonstrated how substantially the outlook for advanced melanoma had changed. With at least 10 years of follow-up, median overall survival was 71.9 months with nivolumab plus ipilimumab, 36.9 months with nivolumab alone and 19.9 months with ipilimumab alone.<\/p>\n\n\n\n

These results demonstrate durable long-term benefit from PD-1-containing treatment, but they do not mean that combination nivolumab plus ipilimumab is the best option for every patient. Treatment choice depends on factors including toxicity risk, general health, performance status, brain metastases, tumour biology and individual preferences. NICE guideline NG14 recommends nivolumab plus ipilimumab when suitable, with nivolumab or pembrolizumab monotherapy when this combination is unsuitable or unacceptable. NICE technology appraisal TA950 also recommends nivolumab\u2013relatlimab as an option for untreated advanced melanoma in people aged 12 years and over under its specified conditions.<\/p>\n\n\n\n

Interferon Changed Treatment After Surgery<\/strong><\/h2>\n\n\n\n

Interferon alfa-2b became an important historical treatment for people whose high-risk melanoma had been surgically removed. The ECOG E1684 randomised trial involved 287 patients and reported improvements in both relapse-free survival and overall survival with high-dose interferon compared with observation.<\/p>\n\n\n\n

The study was published in 1996 and helped establish immunotherapy in the adjuvant setting, although later melanoma treatment moved increasingly towards checkpoint inhibitors. Current NICE melanoma pathways now include modern checkpoint immunotherapies rather than interferon as the key systemic immunotherapy options.<\/p>\n\n\n\n

Scientists Began Studying Immune Checkpoints<\/strong><\/h2>\n\n\n\n

Researchers discovered that immune cells have natural \u201cbrakes\u201d that limit excessive immune activity. This led scientists to explore whether releasing these brakes could help T cells attack cancer cells more effectively.<\/p>\n\n\n\n